NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

疫苗技術:全球市場

Global Markets for Vaccine Technologies

出版商 BCC Research 商品編碼 955511
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
疫苗技術:全球市場 Global Markets for Vaccine Technologies
出版日期: 2020年08月21日內容資訊: 英文 200 Pages
簡介

全球疫苗技術市場預計將以6.3%的複合年增長率增長,2019年將達到401億美元,2020年將達到426億美元,2025年將達到578億美元。

本報告分析了全球疫苗技術市場,並分析了疫苗的特徵,目標疾病/製造方法,基本市場結構和促銷/抑制因素,市場規模趨勢展望以及按類型/地區劃分的詳細信息。我們正在調查趨勢,主要公司的概況和業務發展狀況。

目錄

第1章簡介

第2章摘要要點

第3章市場/技術背景

  • 定義
  • 免疫系統和疫苗
    • 疫苗如何起作用?
    • 免疫類型
    • 接種疫苗的好處
    • 疫苗的歷史
  • 疫苗類型
    • 減毒(活疫苗)
    • 滅活□□(滅活)疫苗
    • 類毒素疫苗
    • 亞單位疫苗
    • 結合疫苗
    • 重組載體疫苗
    • DNA疫苗
    • RNA疫苗
    • 佐劑和賦形劑
    • 病原細菌成分
    • 顆粒佐劑
  • 可以通過疫苗預防的傳染病
    • 人類疾病
    • 病毒性疾病
    • 細菌性疾病
    • 動物疾病
    • 家畜
    • 伴侶動物
    • 其他動物
    • 快速生產大流行疫苗
  • 疫苗生產方法的類型
    • 植物疫苗
    • 雞蛋疫苗生產
    • 細胞疫苗
    • 臨床疫苗的製造方法
  • 疫苗的臨床開發
    • 大流行疫苗的臨床開發
    • 法律
    • 大流行性疾病疫苗的分發
    • 政府的努力
    • 最新技術和公司
    • 快速製造等技術進步
    • 全球範圍內的疫苗接種增加
    • 政府對疫苗開發的支持
    • 低收入國家缺乏認識
  • 市場機會
    • RNA疫苗接種
    • 抗生素耐藥性上升
    • 現狀
    • 人類疫苗市場的動態
    • 動物疫苗市場的動態
  • 監管方面
    • 世界衛生組織(WHO)的預認證疫苗
    • 新產品批准
    • 召回
    • 疫苗不足
    • 疫苗可預防疾病產品的重大法規發展

第4章細分市場:用於人類疫苗

  • 人疫苗:按類型
    • 減毒(活疫苗)
    • 滅活□□疫苗
    • 結合疫苗
    • DNA/rDNA疫苗
    • 亞單位疫苗
    • 類毒素疫苗
    • 其他/組合疫苗
  • 特定年齡的疫苗
    • 小兒疫苗
    • 青少年/成人疫苗
    • 老年人疫苗
  • 按疾病類型劃分的疫苗
    • 白喉
    • 流感
    • A型肝炎
    • 麻疹
    • 輪狀病毒
    • 囊泡
    • 結合其他疾病的疫苗
  • 疾病爆發
  • 疫苗接種途徑
    • 肌內注射
    • 皮內注射
    • 粘膜疫苗
    • 納米貼片

第5章市場類別:用於動物疫苗

  • 動物疫苗
  • 按類型劃分的市場

第6章按地區劃分的市場分類

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太國家
  • 其他國家(行)

第7章COVID-19對現在和未來的影響

  • COVID-19對疫苗供應的影響
  • 低收入國家由於大規模感染而造成進一步疾病流行的風險

第8章公司簡介

  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAXTER INTERNATIONAL INC.
  • BAYER ANIMAL HEALTH
  • BHARAT BIOTECH INTERNATIONAL LTD.
  • BIOLOGICAL E. LTD.
  • BIO-MANGUINHOS
  • BIOPROPERTIES PTY LTD.
  • BOEHRINGER INGELHEIM GMBH
  • BUL BIO NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.)
  • CADILA HEALTHCARE LTD. (ZYDUS CADILA)
  • CEVA SANTE ANIMALE
  • CHINA NATIONAL BIOTEC GROUP (CNBG)
  • COLORADO SERUM CO.
  • CSL LTD.
  • ELANCO ANIMAL HEALTH
  • EMERGENT BIOSOLUTIONS INC.
  • FATRO SPAVIA
  • GE HEALTHCARE
  • GENEONE LIFE SCIENCES INC.
  • PRECIGEN INC. (FORMERLY INTREXON)
  • GEOVAX
  • GLAXOSMITHKLINE PLC
  • GREEN CROSS CORP.
  • IBIO INC.
  • INSTITUT PASTEUR DE DAKAR
  • JOHNSON & JOHNSON INC.
  • LG LIFE SCIENCES
  • MAXCYTE INC.
  • MERCK & CO., INC.
  • NOVARTIS PHARMA AG
  • PANACEA BIOTEC LTD.
  • PFENEX INC.
  • PFIZER INC.
  • PROFECTUS BIOSCIENCES INC.
  • PT BIO FARMA
  • REPLIKINS LTD.
  • SANOFI PASTEUR
  • SERUM INSTITUTE OF INDIA LTD.
  • STATENS SERUM INSTITUT
  • THERMO FISHER SCIENTIFIC
  • VALNEVA SE
  • VIRBAC
  • ZOETIS INC.
目錄
Product Code: PHM014H

Highlights:

The global market for vaccine technologies totaled $40.1 billion in 2019. The market should grow from $42.6 billion in 2020 to $57.8 billion by 2025, at a compound annual growth rate (CAGR) of 6.3% during the 2020-2025 forecast period.

The global market for human vaccine technologies should grow from $34.8 billion in 2020 to $47.8 billion by 2025, at a CAGR of 6.6% during the 2020-2025 forecast period.

The global market for animal vaccine technologies should grow from $7.8 billion in 2020 to $10.0 billion by 2025, at a CAGR of 5.1% during the 2020-2025 forecast period.

Report Scope:

The report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors, and provides insights to stakeholders and potential entrants.

Broadly speaking, depending on whether they prevent diseases or treat pre-existing ones, vaccines can be divided into prophylactic and therapeutic vaccines. In contrast, animal vaccines are categorized by food-producing animals (porcine, bovine, poultry, ovine, fish) and companion animals (canine, feline and equine vaccines), as well as vaccines for other animal species.

This study looks at most of the systems affected by factors such as considerable research and development (R&D) spending and increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth.

Company merger acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type considering new technologies, growing competition and changing customer needs.

The market has also been analyzed based on the application of current vaccines. Categories considered in this report include meningococcal/pneumococcal vaccines, influenza vaccines, pediatric polio/pertussis/Hib vaccines, adult/adolescent booster vaccines, vaccines for travel-related and other endemic diseases, HPV vaccines, rotavirus vaccines and other (minor) vaccines.

This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories and various hospital settings, as well as pharmaceutical, diagnostic and biotechnology companies and physicians, will find this study to be of interest.

The report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding their geographic reach will also find this study useful.

Report Includes:

  • 34 data tables and 54 additional tables
  • Descriptive overview of the global markets for vaccine technologies and their applications
  • Analyses of the global market trends, with data from 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Evaluation of the current market size, market estimation and forecast, pipeline analysis of new products; and discussion of opportunities, drivers and challenges affecting the overall marketplace
  • Brief general outlook of the recent market developments, technological advancements, government regulations and policies, patent analyses and upcoming technologies, R&D activities related to the vaccine technology industry
  • Identification of present and future strategies within the vaccine technology market and examination of vaccines for both humans and animals
  • Opportunities and highlights of this innovation-driven vaccine technologies market, and the major regions and countries involved in market developments and their immunization schedule
  • A separate chapter on COVID-19 pandemic impact on the present and future vaccines market, major COVID-19 vaccine candidates under development, and impact of outbreak on vaccine supplies
  • Detailed company profiles of the market leading participants, including Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, Bayer Animal Health, GlaxoSmithKline (GSK), Merck & Co. Inc., Johnson & Johnson Inc., Novartis, Pfizer, Sanofi Pasteur and Thermo Fisher Scientific

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Definitions
  • Immune System and Vaccines
    • How Vaccines Work?
    • Types of Immunity
    • Advantages of Vaccination
  • History of Vaccines
  • Types of Vaccines
    • Attenuated (Live) Vaccines
    • Inactivated (Killed) Vaccines
    • Toxoid Vaccines
    • Subunit Vaccines
    • Conjugate Vaccines
    • Recombinant Vector Vaccines
    • DNA Vaccines
    • RNA Vaccines
  • Adjuvants and Excipients
    • Pathogen Components
    • Particulate Adjuvants
  • Infectious Diseases Preventable by Vaccines
  • Human Diseases
    • Viral Diseases
    • Bacterial Diseases
  • Animal Diseases
    • Food-Producing Animals
    • Companion Animals
    • Other Animals
  • Rapid Manufacturing for Pandemics
  • Types of Vaccine Manufacturing Methods
    • Plant-Based Vaccines
    • Egg-Based Vaccine Manufacturing
    • Cell-Based Vaccines
  • Investigational Vaccine Manufacturing Methods
  • Clinical Development of Vaccines
  • Clinical Development of Pandemic Vaccines
    • Laws and Regulations
  • Vaccine Distribution in the Case of Pandemic Diseases
  • Government Initiatives
  • Recent Technologies and Companies
    • Technological Advancements Such as Rapid Manufacturing
  • Rising Immunization across the Globe
  • Government Support for Vaccine Development
  • Lack of Awareness in Low-Income Countries
  • Opportunities
    • RNA Vaccination
    • Rise of Antibiotic Resistance
  • Current Situation
    • Dynamics of the Market for Human Vaccines
    • Dynamics of the Market for Animal Vaccines
  • Regulatory Aspects
    • World Health Organization (WHO) Prequalified Vaccines
    • New Product Approvals
    • Recalls
    • Vaccine Shortage
    • Significant Regulatory Developments in Vaccine-Preventable Disease Products

Chapter 4: Market Breakdown by Human Vaccine

  • Human Vaccines by Type
    • Attenuated (Live) Vaccines
    • Inactivated Vaccines
    • Conjugate Vaccines
    • DNA/rDNA Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
    • Other/Combination Vaccines
  • Vaccines by Age Group
    • Pediatric Vaccines
    • Vaccines for Adolescents and Adults
    • Vaccines for the Geriatric Population
  • Vaccine by Disease Type
    • Diptheria
    • Influenza
    • Hepatitis A
    • Measles
    • Rotavirus
    • Chickenpox
    • Other Diseases and Combination Vaccines
    • Outbreak of Diseases
  • Vaccines by Delivery Route
    • Intramuscular Injection
    • Intradermal Injection
    • Mucosal Vaccination
    • Nanopatch

Chapter 5: Market Breakdown by Animal Vaccine

  • Animal Vaccines
  • Market by Type

Chapter 6: Market Breakdown by Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Rest of APAC
  • Rest of the World

Chapter 7: COVID-19 Impact on Present and Future

  • Impact of COVID-19 on Vaccine Supplies
    • Massive Impact on Lower-Income Countries Threatens More Disease Outbreaks

Chapter 8: Company Profiles

  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAXTER INTERNATIONAL INC.
  • BAYER ANIMAL HEALTH
  • BHARAT BIOTECH INTERNATIONAL LTD.
  • BIOLOGICAL E. LTD.
  • BIO-MANGUINHOS
  • BIOPROPERTIES PTY LTD.
  • BOEHRINGER INGELHEIM GMBH
  • BUL BIO NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.)
  • CADILA HEALTHCARE LTD. (ZYDUS CADILA)
  • CEVA SANTE ANIMALE
  • CHINA NATIONAL BIOTEC GROUP (CNBG)
  • COLORADO SERUM CO.
  • CSL LTD.
  • ELANCO ANIMAL HEALTH
  • EMERGENT BIOSOLUTIONS INC.
  • FATRO SPAVIA
  • GE HEALTHCARE
  • GENEONE LIFE SCIENCES INC.
  • PRECIGEN INC. (FORMERLY INTREXON)
  • GEOVAX
  • GLAXOSMITHKLINE PLC
  • GREEN CROSS CORP.
  • IBIO INC.
  • INSTITUT PASTEUR DE DAKAR
  • JOHNSON & JOHNSON INC.
  • LG LIFE SCIENCES
  • MAXCYTE INC.
  • MERCK & CO., INC.
  • NOVARTIS PHARMA AG
  • PANACEA BIOTEC LTD.
  • PFENEX INC.
  • PFIZER INC.
  • PROFECTUS BIOSCIENCES INC.
  • PT BIO FARMA
  • REPLIKINS LTD.
  • SANOFI PASTEUR
  • SERUM INSTITUTE OF INDIA LTD.
  • STATENS SERUM INSTITUT
  • THERMO FISHER SCIENTIFIC
  • VALNEVA SE
  • VIRBAC
  • ZOETIS INC.

List of Tables

  • Summary Table: Global Market for Vaccine Technologies, by Segment, Through 2025
    • Table 1: History of Vaccines, by Year
    • Table 2: Types of Attenuated (Live) Vaccines, by Segment
    • Table 3: Advantages and Disadvantages of Attenuated (Live) Vaccines
    • Table 4: Types of Inactivated (Killed) Vaccines, by Segment
    • Table 5: Advantages and Disadvantages of Inactivated (Killed) Vaccines
    • Table 6: Types of Toxoid Vaccines, by Segment
    • Table 7: Advantages and Disadvantages of Toxoid Vaccines
    • Table 8: Types of Subunit Vaccines, by Segment
    • Table 9: Advantages and Disadvantages of Subunit Vaccines
    • Table 10: Types of Conjugate Vaccines, by Segment
    • Table 11: Advantages and Disadvantages of Conjugate Vaccines
    • Table 12: Types of Recombinant Vector Vaccines, by Segment
    • Table 13: Advantages and Disadvantages of Recombinant Vector Vaccines
    • Table 14: Types of DNA Vaccines, by Segment
    • Table 15: Advantages and Disadvantages of DNA Vaccines
    • Table 16: Advantages and Disadvantages of RNA Vaccines
    • Table 17: Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines
    • Table 18: Vaccine-Preventable Human Viral Diseases
    • Table 19: Vaccine-Preventable Human Bacterial Diseases
    • Table 20: Vaccine-Preventable Parasitic Animal Diseases Found in Food-Producing Animals
    • Table 21: Vaccine-Preventable Bacterial Animal Diseases Found in Food-Producing Animals
    • Table 22: Vaccine-Preventable Viral Animal Diseases Found in Food-Producing Animals
    • Table 23: Vaccine-Preventable Parasitic Animal Diseases Found in Companion Animals
    • Table 24: Vaccine-Preventable Bacterial Animal Diseases Found in Companion Animals
    • Table 25: Vaccine-Preventable Viral Animal Diseases Found in Companion Animals
    • Table 26: Vaccine-Preventable Viral Animal Diseases Found in Other Animals
    • Table 27: Vaccine-Preventable Viral Animal for Food-Producing in Companion
    • Table 28: Cases of Diphtheria, by Country, 2011-2015
    • Table 29: Petitions Filed, Compensated and Dismissed about Vaccinessince the Beginning of VICP, 1998-2020
    • Table 30: WHO Prequalified Vaccines, January 2014-April 2020
    • Table 31: Newly Approved Vaccines, January 2014-April 2020
    • Table 32: Global Vaccine Recalls, by Manufacturer, January 2014-November 2017
    • Table 33: Global Vaccine Shortage, by Manufacturer, January 2012-November 2017
    • Table 34: Global Market for Human Vaccines, by Type, Through 2025
    • Table 35: Global Market for Attenuated (Live) Vaccines, by Region, Through 2025
    • Table 36: Global Market for Inactivated (Killed) Vaccines, by Region, Through 2025
    • Table 37: Global Market for Conjugate Vaccines, by Region, Through 2025
    • Table 38: Global Market for Recombinant/rDNA/DNA Vaccines, by Region, Through 2025
    • Table 39: Global Market for Subunit Vaccines, by Region,Through 2025
    • Table 40: Global Market for Toxoid Vaccines, by Region, Through 2025
    • Table 41: Global Market for Other/Combination Vaccines, by Region, Through 2025
    • Table 42: Global Market for Human Vaccines, by Age Group, Through 2025
    • Table 43: Pediatric Vaccines Doses
    • Table 44: Pediatric/VFC Vaccine Price List, 2019
    • Table 45: Influenza Vaccine Price List, 2020
    • Table 46: Pediatric Vaccines Doses, by Age Group
    • Table 47: Global Market for Human Vaccines for Pediatrics, by Region, Through 2025
    • Table 48: Global Market for Human Vaccines for Adults, by Region, Through 2025
    • Table 49: Adult Vaccine Price List
    • Table 50: Vaccine Price List for Geriatric Population
    • Table 51: Global Market for Human Vaccines for Geriatrics, by Region, Through 2025
    • Table 52: Vaccines, by Disease Type
    • Table 53: Global Market for Human Vaccines, by Disease Type, Through 2025
    • Table 54: Global Market for Meningococcal/Pneumococcal Vaccines, by Region, Through 2025
    • Table 55: Global Market for Influenza Vaccines, by Region, Through 2025
    • Table 56: Global Market for Pediatric Polio/Pertussis/Hib Vaccines, by Region, Through 2025
    • Table 57: Global Market for Rotavirus Diseases Vaccines, by Region, Through 2025
    • Table 58: Global Market for Endemic Diseases Vaccines, by Region, Through 2025
    • Table 59: Global Market for HPV Vaccines, by Region, Through 2025
    • Table 60: Global Market for Adult/Adolescent Booster Vaccines, by Region, Through 2025
    • Table 61: Global Market for Other Diseases Vaccines, by Region, Through 2025
    • Table 62: Seasonal Influenza Vaccines
    • Table 63: Vaccine, by Route of Delivery
    • Table 64: Site for Intramuscular Immunization, by Age
    • Table 65: Nasal Vaccines, by Disease
    • Table 66: Global Market for Animal Vaccines, by Type, Through 2025
    • Table 67: Global Market for Food-Producing Animals Vaccines, by Region, Through 2025
    • Table 68: Global Market for Companion Animals Vaccines, by Region, Through 2025
    • Table 69: Global Market for Other Animal Vaccines, by Region, Through 2025
    • Table 70: UNICEF Vaccination Price and Major Suppliers, 2020
    • Table 71: Estimated Life Saved due to Vaccination, 2011-2020 (Assuming No Vaccination as the Counterfactual)
    • Table 72: U.S. Recommended Immunization Schedule, by Vaccine Type, 2020
    • Table 73: Vaccine Price List, 2019
    • Table 74: Immunization Schedule of Canada, 2020
    • Table 75: Immunization Schedule of Germany, 2020
    • Table 76: Immunization Schedule of France, 2020
    • Table 77: Vaccination and Immunization Schedule of the U.K., 2020
    • Table 78: Immunization Schedule of Italy, 2020
    • Table 79: Immunization Schedule of China, 2020
    • Table 80: Immunization Schedule of Japan, 2020
    • Table 81: Immunization Schedule of India, 2020
    • Table 82: Number of Reported Cases in India, 2013-2016
    • Table 83: GAVI Support to India, 2001-2021
    • Table 84: Africa WHO/UNICEF Vaccination Coverage Estimate, 2014-2019
    • Table 85: Middle East WHO/UNICEF Vaccination Coverage Estimate, 2014-2019
    • Table 86: Global Market for Human Vaccines, by Region, Through 2025
    • Table 87: Major COVID-19 Vaccine Candidates Under Development

List of Figures

  • Summary Figure: Global Market for Vaccine Technologies, by Segment, 2019-2025
    • Figure 1: Literacy Rates in Population Above 15 Years of Age in Selected Countries, 2015
    • Figure 2: Infants Lacking Immunization Measles, 2018
    • Figure 3: Polio Cases in the U.S., 1950-2015
    • Figure 4: Percentage of Children Aged 19-35 Months Receiving Vaccinations in the U.S., 2019
    • Figure 5: Globally Immunization Coverage, 2019
    • Figure 6: Seasonal Flu Vaccination Coverage in the U.S., 2013-2019
    • Figure 7: Globally Immunization Coverage, 2013-2019
    • Figure 8: Diphtheria Cases in the U.S., 1945-2015
    • Figure 9: Seasonal Flu Vaccination Coverage in the U.S., 2013-2019
    • Figure 10: WHO/UNICEF Vaccine Coverage Estimate, 2018 and 2019
    • Figure 11: Hepatitis A Cases in the U.S., 1990-2019
    • Figure 12: Measles Cases in the U.S., 1960-2019
    • Figure 13: Chickenpox Cases in the U.S., 1975-2014
    • Figure 14: Global Immunization Coverage, 2019
    • Figure 15: Shares of Donor Contributions to GAVI Alliance, 2000-2020
    • Figure 16: Global Investment in R&D Vaccination, 2012-2015
    • Figure 17: Donation from the U.S. to GAVI Alliance, 2013-2018
    • Figure 18: Canada's Cash Funding to GAVI Alliance, 2014-2018
    • Figure 19: Germany's Funding to GAVI Alliance, 2013-2018
    • Figure 20: France's Funding to GAVI Alliance, 2012-2015
    • Figure 21: U.K.'s Funding to GAVI Alliance, 2000-2036
    • Figure 22: Donations from European Governments and Organizations to GAVI, 2013-2018
    • Figure 23: Investment by APAC Counties in Vaccination R&D, 2012-2019
    • Figure 24: Shares of Chinese Funding to GAVI Alliance, 2001-2021
    • Figure 25: Japan's Funding to GAVI Alliance, 2011-2020
    • Figure 26: Australia's Funding to GAVI Alliance, 2013-2017